Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Feb:95:20-25.
doi: 10.1016/j.bone.2016.11.009. Epub 2016 Nov 11.

Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study

J N Tsai  1 , S M Burnett-Bowie  2 , H Lee  3 , B Z Leder  2
Affiliations
Randomized Controlled Trial

Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study

J N Tsai et al. Bone. 2017 Feb.

Abstract

Background: While changes in biochemical markers of bone turnover (BTM) have been reported to predict changes in bone mineral density (BMD), the relationship between changes in BMD and BTMs with combined antiresorptive/anabolic therapy is unknown.

Methods: In the DATA study, 94 postmenopausal osteoporotic women (ages 51-91) received either teriparatide 20-mcg SC daily, denosumab 60-mg SC every 6months, or both for 2years. Pearson's correlation coefficients (R) were calculated to determine the relationship between baseline and early changes in BTMs (as well as serum sclerostin) and 2-year changes in BMD.

Results: In women receiving teriparatide, baseline BTMs did not correlate with 2-year BMD changes though 12-month increases in osteocalcin and P1NP were associated with 2-year increases in spine BMD. In women receiving denosumab, spine and hip BMD gains correlated with both baseline and changes in P1NP and C-telopeptide. In women receiving combined teriparatide/denosumab, while both baseline and decreases in P1NP were associated with spine BMD gains, distal radius increases were associated with less CTX suppression. Neither baseline nor changes in serum sclerostin correlated with BMD in any treatment group.

Summary and conclusions: In women treated with teriparatide or denosumab, early BTM changes (increases and decreases, respectively) predict 2-year BMD gains, especially at the spine. In women treated with combined teriparatide/denosumab therapy, BMD increases at the distal radius were associated with less suppression of bone turnover. These results suggest that efficacy of combination therapy at cortical sites such as the radius may depend on residual bone remodeling despite RANKL inhibition.

Keywords: Bone formation; Bone resorption; Bone turnover markers; Denosumab; Osteoporosis; Teriparatide.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean (SEM) percent change in bone turnover markers A. Teriparatide B. Denosumab alone and teriparatide and denosumab combined. Data for teriparatide-alone group are shown separately for clarity. *p<0.05 vs. baseline. a p<0.001 vs denosumab and vs combined therapy. b p<0.01 vs denosumab. TPTD=teriparatide. DMAB=denosumab.
Figure 2
Figure 2
Mean (SEM) percent change in serum sclerostin. P<0.05 at all timepoints for all groups versus baseline.
Figure 3
Figure 3
12-month change in P1NP correlated to spine BMD change in women who received teriparatide (A) or denosumab (B).
Figure 4
Figure 4
Change in CTX correlated to 1/3 radius BMD change in women who received combination denosumab and teriparatide.
See this image and copyright information in PMC

References

    1. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2005;20:962–70. - PubMed
    1. Blumsohn A, Marin F, Nickelsen T, Brixen K, Sigurdsson G, Gonzalez de la Vera J, Boonen S, Liu-Leage S, Barker C, Eastell R, Group ES. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2011;22:1935–46. - PMC - PubMed
    1. Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH. PINP as an aid for monitoring patients treated with teriparatide. Bone. 2011;48:798–803. - PubMed
    1. Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2011;26:530–7. - PubMed
    1. Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, Lee H, Neer RM. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. The Journal of clinical endocrinology and metabolism. 2014;99:1694–700. - PMC - PubMed

Publication types

MeSH terms